Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Interest & Investment Income: 2014-2024

Historic Interest & Investment Income for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to $40.9 million.

  • Viking Therapeutics' Interest & Investment Income fell 32.60% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.5 million, marking a year-over-year increase of 7.79%. This contributed to the annual value of $40.9 million for FY2024, which is 172.57% up from last year.
  • Latest data reveals that Viking Therapeutics reported Interest & Investment Income of $40.9 million as of FY2024, which was up 172.57% from $15.0 million recorded in FY2023.
  • In the past 5 years, Viking Therapeutics' Interest & Investment Income registered a high of $40.9 million during FY2024, and its lowest value of $703,000 during FY2021.
  • In the last 3 years, Viking Therapeutics' Interest & Investment Income had a median value of $15.0 million in 2023 and averaged $19.2 million.
  • As far as peak fluctuations go, Viking Therapeutics' Interest & Investment Income slumped by 78.26% in 2021, and later spiked by 845.25% in 2023.
  • Over the past 5 years, Viking Therapeutics' Interest & Investment Income (Yearly) stood at $3.2 million in 2020, then slumped by 78.26% to $703,000 in 2021, then soared by 126.03% to $1.6 million in 2022, then soared by 845.25% to $15.0 million in 2023, then spiked by 172.57% to $40.9 million in 2024.